[ad_1]

Important points

  • Merck & Co.’s stock soared to an all-time high Wednesday, a day after the Food and Drug Administration approved the company’s treatment for a rare cardiovascular disease.
  • The drug, named Winrevair, is for patients suffering from pulmonary arterial hypertension (PAH), a condition in which blood pressure increases due to restriction of the pulmonary arteries.
  • Merck & Co. called Winrevair the first drug for PAH.

Merck & Company (MRK) stock hit an all-time high on Wednesday, a day after the company announced that the Food and Drug Administration (FDA) has approved food regulations to treat a rare disease that causes high blood pressure in patients. Recorded. their pulmonary arteries.

The injectable drug, known by the trade name Winrevair, is for adults suffering from pulmonary arterial hypertension (PAH). The company explained that Winrevair helps users improve their athletic performance and reduce the risk of worsening health events.

Merck said Winrevair is the first FDA-approved activin signaling inhibitor therapy for PAH and represents a new type of treatment. The company noted that the FDA had previously granted it breakthrough therapy designation.

Mark Humbert, an investigator on Winrevair’s Phase 3 study, called the approval “an important milestone as it provides healthcare providers with new treatment options targeting new PAH treatment pathways.” Ta.

Winrevair reportedly costs $14,000 per dose and patients receive injections once every three weeks to treat the disease, which affects nearly 40,000 people in the United States. Merck & Co., which paid $11.5 billion in 2021 to develop the drug, has infected more than 40 people. % of sales come from the cancer drug Keytruda, which is the world’s best-selling drug.

Merck’s stock price rose 3.9% to $130.46 as of 11:50 a.m. ET Wednesday, after hitting a record high of $133.10 in early trading. It’s up almost 20% since the beginning of this year.

TradingView


[ad_2]

Source link